This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2018 Jun;15(3):240-242.

doi: 10.1177/1740774518770660.

Access versus evidence: The regulators' dilemma

Richard L Schilsky¹

Affiliations

PMID: 29871504
DOI: 10.1177/1740774518770660

Comment

Access versus evidence: The regulators' dilemma

Richard L Schilsky. Clin Trials. 2018 Jun.

. 2018 Jun;15(3):240-242.

doi: 10.1177/1740774518770660.

Author

Richard L Schilsky¹

Affiliation

¹ American Society of Clinical Oncology, Alexandria, VA, USA.

PMID: 29871504
DOI: 10.1177/1740774518770660

No abstract available

PubMed Disclaimer

Comment in

The US Food and Drug Administration's expedited approval programs: Addressing premarket flexibility with enhanced postmarket evidence generation.
Wallach JD, Ross JS, Naci H. Wallach JD, et al. Clin Trials. 2018 Jun;15(3):243-246. doi: 10.1177/1740774518770657. Clin Trials. 2018. PMID: 29871507 No abstract available.

Comment on

The US Food and Drug Administration's expedited approval programs: Evidentiary standards, regulatory trade-offs, and potential improvements.
Wallach JD, Ross JS, Naci H. Wallach JD, et al. Clin Trials. 2018 Jun;15(3):219-229. doi: 10.1177/1740774518770648. Clin Trials. 2018. PMID: 29871509

Publication types

Actions

MeSH terms

Actions
Actions

LinkOut - more resources

Full Text Sources
- Atypon
Other Literature Sources
- scite Smart Citations